Nebenwirkungen · Vaxneuvance
Vaxneuvance suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 7
HOS-147688 · Präparat HOS-099718
The safety of Vaxneuvance in healthy and immunocompetent adults was assessed in 6 clinical studies in 7 136 adults ≥18 years of age. An additional clinical study assessed 302 adults ≥18 years of age living with HIV. Vaxneuvance was administered to 5 630 adults; 1,241 were 18 to 49 years of age, 1 911 were 50 to 64 years of age, and 2 478 were 65 years of age and older. Of those who received Vaxneuvance, 1 134 were immunocompetent adults 18 to 49 years of age who had no (n=285), 1 (n=620) or ≥ 2 (n=229) risk factors for pneumococcal disease and 152 were adults ≥18 years of age living with HIV.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-16T14:19:00Z · SHA-256 8c806efad2c6480965326c02c35aa390b1a5f1070feca6a9495a17a403d294b7 · Passage 6990e955130f1a770bd1af2380d12fe7cd2fa5dbf8eab7a661598f20b3ffd1f8 · Zeichen 2115–2714 im Abschnitt